Rapid Micro Bio pre-announces Q4 rev $4.7-5.2M; FY22 outlook $27-32M

RAPID MICRO BIOSYSTEMS, INC.

2021-FY EPS reported -$3.94 revenue$23,232,000

Preliminary Q4 total revenue $4.7M-$5.2M; commercial $4.5M-$4.9M; non-commercial (BARDA) $0.2M-$0.3M.
Full year 2021 total revenue $22.8M-$23.3M; commercial $21.3M-$21.7M; placed 29 systems, validated 33.
Recurring revenue grew ~90% in Q4 vs prior-year period; 16 systems validated in Q4.
FY2022 commercial revenue outlook $27M-$32M, 25%-50% growth over preliminary FY2021 commercial revenue.
Ended 2021 with >$200M cash and investments, zero debt; COVID headwinds impacted Q4 placements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.